Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis-Reference-Cited by-同舟云学术

Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis

Published:2017-11-21 Issue:2 Volume:47 Page:219-228
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Colombel J.-F.¹^ORCID,Sandborn W. J.²,Reinisch W.³,Peyrin-Biroulet L.⁴,Panaccione R.⁵,Rutgeerts P.⁶,Hanauer S. B.⁷^ORCID,Ghosh S.⁵,Van Assche G.⁶,Robinson A. M.⁸,Lau W.⁸,Maa J.-F.⁸,Huang B.⁸,Pappalardo B.⁸,Read H.⁸

Affiliation:

1. New York NY USA

2. La Jolla CA USA

3. Vienna Austria

4. Vandoeuvre-les-Nancy France

5. Calgary AB Canada

6. Leuven Belgium

7. Chicago IL USA

8. North Chicago; IL USA

Funder

AbbVie

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14420/fullpdf

Reference31 articles.

1. Humira ® (adalimumab). Full prescribing information 2015

2. Humira summary of product characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf

3. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial;Colombel;Gastroenterology,2007

4. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial;Sandborn;Gut,2007

5. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial;Hanauer;Gastroenterology,2006

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn’s Disease;Digestive Diseases and Sciences;2024-04-03

2. Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn’s Disease and Ulcerative Colitis;Gastroenterology Research;2023-12

3. The 2023 Impact of Inflammatory Bowel Disease in Canada: Access to and Models of Care;Journal of the Canadian Association of Gastroenterology;2023-09-01

4. Optical coherence tomography changes in ankylosing spondylitis patients on long-term adalimumab treatment;Revista da Associação Médica Brasileira;2022-11-25

5. Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis;European Journal of Medical Research;2022-09-30